Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's…
Read the full articleYou might also wanna read
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise
Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial prof
This Stock Is Up 74% This Year: Is It Too Late to Buy?
The biotech is clearly innovative, but sometimes that's not enough.
Comments
Sign in to join the conversation.
No comments yet. Be the first.